BR112018075363A2 - neurotoxinas botulínicas manipuladas - Google Patents
neurotoxinas botulínicas manipuladasInfo
- Publication number
- BR112018075363A2 BR112018075363A2 BR112018075363-7A BR112018075363A BR112018075363A2 BR 112018075363 A2 BR112018075363 A2 BR 112018075363A2 BR 112018075363 A BR112018075363 A BR 112018075363A BR 112018075363 A2 BR112018075363 A2 BR 112018075363A2
- Authority
- BR
- Brazil
- Prior art keywords
- manipulated
- modified
- serotype
- botulinum neurotoxins
- receptor binding
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 3
- 241000193155 Clostridium botulinum Species 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 101100272852 Clostridium botulinum (strain Langeland / NCTC 10281 / Type F) F gene Proteins 0.000 abstract 1
- 101710138657 Neurotoxin Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002581 neurotoxin Substances 0.000 abstract 1
- 231100000618 neurotoxin Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347579P | 2016-06-08 | 2016-06-08 | |
| US62/347,579 | 2016-06-08 | ||
| PCT/US2017/036628 WO2017214447A1 (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075363A2 true BR112018075363A2 (pt) | 2019-03-19 |
Family
ID=59227906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075363-7A BR112018075363A2 (pt) | 2016-06-08 | 2017-06-08 | neurotoxinas botulínicas manipuladas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11104891B2 (https=) |
| EP (1) | EP3468985A1 (https=) |
| JP (2) | JP7152392B2 (https=) |
| KR (1) | KR20190025906A (https=) |
| CN (1) | CN109476713A (https=) |
| AU (1) | AU2017277905B2 (https=) |
| BR (1) | BR112018075363A2 (https=) |
| CA (1) | CA3026492A1 (https=) |
| EA (1) | EA201892784A1 (https=) |
| IL (1) | IL263058B2 (https=) |
| MX (1) | MX2018015254A (https=) |
| SG (2) | SG11201810210UA (https=) |
| WO (1) | WO2017214447A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606666XA (en) | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| PT3274364T (pt) * | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| US11242515B2 (en) * | 2016-05-16 | 2022-02-08 | President And Fellows Of Harvard College | Method for purification and activation of botulinum neurotoxin |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US12098169B2 (en) | 2017-09-29 | 2024-09-24 | Children's Medical Center Corporation | Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof |
| TWI810228B (zh) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| WO2019152380A1 (en) | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| CN114957482B (zh) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
| KR20230001254A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
| KR20230001260A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
| WO2023068485A1 (ko) * | 2021-10-22 | 2023-04-27 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물 |
| WO2023089343A1 (en) * | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| CN114410683B (zh) * | 2022-01-12 | 2023-11-28 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的RIM3-RNAi及其应用 |
| CN114369623B (zh) * | 2022-01-12 | 2023-07-07 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用 |
| GB202206348D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| KR102728382B1 (ko) * | 2022-10-12 | 2024-11-14 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
| WO2025065012A1 (en) * | 2023-09-21 | 2025-03-27 | The Medical College Of Wisconsin, Inc. | Botulinum neurotoxin variants, constructs, compositions, and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| PT1086702E (pt) | 1994-05-09 | 2005-08-31 | William J Binder | Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| EP2366787B1 (en) * | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| US8273865B2 (en) | 2006-03-15 | 2012-09-25 | Allergan, Inc. | Multivalent clostridial toxins |
| SG10201606666XA (en) * | 2012-05-30 | 2016-09-29 | Harvard College | Engineered Botulinum Neurotoxin |
| EP3270951B1 (en) * | 2015-03-16 | 2020-09-09 | California Institute of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2017
- 2017-06-08 CN CN201780035648.4A patent/CN109476713A/zh active Pending
- 2017-06-08 IL IL263058A patent/IL263058B2/en unknown
- 2017-06-08 KR KR1020197000585A patent/KR20190025906A/ko not_active Ceased
- 2017-06-08 JP JP2019516917A patent/JP7152392B2/ja active Active
- 2017-06-08 SG SG11201810210UA patent/SG11201810210UA/en unknown
- 2017-06-08 EA EA201892784A patent/EA201892784A1/ru unknown
- 2017-06-08 BR BR112018075363-7A patent/BR112018075363A2/pt not_active IP Right Cessation
- 2017-06-08 EP EP17733667.4A patent/EP3468985A1/en not_active Withdrawn
- 2017-06-08 SG SG10201912099TA patent/SG10201912099TA/en unknown
- 2017-06-08 AU AU2017277905A patent/AU2017277905B2/en not_active Ceased
- 2017-06-08 WO PCT/US2017/036628 patent/WO2017214447A1/en not_active Ceased
- 2017-06-08 US US16/308,146 patent/US11104891B2/en active Active
- 2017-06-08 CA CA3026492A patent/CA3026492A1/en active Pending
- 2017-06-08 MX MX2018015254A patent/MX2018015254A/es unknown
-
2022
- 2022-03-18 JP JP2022044568A patent/JP2022112031A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017277905B2 (en) | 2022-04-14 |
| MX2018015254A (es) | 2019-08-16 |
| KR20190025906A (ko) | 2019-03-12 |
| IL263058B1 (en) | 2023-07-01 |
| AU2017277905A1 (en) | 2018-12-20 |
| CN109476713A (zh) | 2019-03-15 |
| WO2017214447A1 (en) | 2017-12-14 |
| JP7152392B2 (ja) | 2022-10-12 |
| SG10201912099TA (en) | 2020-02-27 |
| IL263058B2 (en) | 2023-11-01 |
| JP2022112031A (ja) | 2022-08-01 |
| US11104891B2 (en) | 2021-08-31 |
| IL263058A (en) | 2018-12-31 |
| JP2019523015A (ja) | 2019-08-22 |
| SG11201810210UA (en) | 2018-12-28 |
| EP3468985A1 (en) | 2019-04-17 |
| CA3026492A1 (en) | 2017-12-14 |
| EA201892784A1 (ru) | 2019-05-31 |
| US20190300869A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075363A2 (pt) | neurotoxinas botulínicas manipuladas | |
| BR112014029585A2 (pt) | neurotoxina botulínica engendrada | |
| BR112019023071A2 (pt) | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas | |
| NZ749810A (en) | A novel botulinum neurotoxin and its derivatives | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| BR112018003782A2 (pt) | composições e métodos para o tratamento da dor | |
| BR112017014060A2 (pt) | composições de bacillus licheniformis rti184 e métodos de uso para beneficiar o crescimento de plantas | |
| BR112019000015A2 (pt) | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos | |
| BR112013027229A2 (pt) | composições que se relacionam a uma toxina de clostridium difficile mutante e métodos para as mesmas | |
| BR112015008844A8 (pt) | composições e métodos relacionados a uma toxina de clostridium difficile mutante | |
| BR112016018598A2 (pt) | vetor de vírus adeno-associados | |
| BR112014017165A8 (pt) | polipeptídeos de fator quimérico viii e seus usos | |
| BR112018000601A2 (pt) | moléculas de anticorpo que se ligam ao cd22 | |
| BR112017007202A2 (pt) | receptores de célula t | |
| BRPI0911385B8 (pt) | polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica | |
| MX2018013784A (es) | Proteinas de fusion gdf15 y usos de estas. | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
| BR112018003753A2 (pt) | bifidobacterium longum | |
| BR112017011398A2 (pt) | métodos e composições que usam polipeptídeos variantes de klotho | |
| MX2017014730A (es) | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). | |
| BR112015014727B8 (pt) | Composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| BR112020006248A8 (pt) | Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer | |
| BR112017001463A2 (pt) | célula hospedeira melhorada para produzir proteínas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2778 DE 02-04-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |